Safety and efficacy of levetiracetam in juvenile patients with focal epilepsy with and without secondary generalisation

The objective of this study was to assess the safety and efficacy of levetiracetam (LEV) (Keppra®) as add-on treatment in juvenile patients with focal epilepsy with or without secondary generalization over 6 months in a German prospective non-interventional study. Patients with uncontrolled seizures received LEV. 3 and 6 months after inclusion the reduction of seizure frequency and the occurrence of adverse events (AE) were recorded. Quality of life (QoL) was assessed using the questionnaire E4. The data of 176 subjects was available for safety analysis, 81 for efficacy analysis. The mean age of the patients was…